Industry F FDA Law Blog
A Day Late, A Buck Short: Or How to Lose PTE Without Really Trying
By Sara W. Koblitz —
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry F FDA Law Blog
By Sara W. Koblitz —
Industry S Science News
Potentially massive illicit trade could be endangering the animals and undermining Indigenous artists
Industry N Nature Reviews Bioengineering
Industry
Nature Biotechnology
Industry N Nature Medicine
Industry N Nature Biomedical Engineering
Industry N Nature Medicine
Industry
BioCentury
BIOCENTURY | DEALSASTELLAS TAKES OPTION ON AUDAX’S IL-12 PROGRAM: DEALS REPORTPlus: BioMarin looks to Korea to expand Fabry franchise; and more
Industry
BioCentury
BIOCENTURY | DATA BYTEPHARMA’S U.S. CONTRIBUTIONS FAVOR INCUMBENTSPharma PACs’ party split roughly tracks the balance of power in Congress
Industry
Drug Discovery and Development
Drug prices are one of the few issues on which Donald Trump has found common ground with progressive Democrats, and with voters in both parties. A March 2026 KFF poll found that 72% of adults say there is not enough government regulation limiting drug prices, including 77% of Dem…
Industry B BioPharm International
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Industry
BioCentury
BIOCENTURY | POLITICS, POLICY & LAWFORMER CDER DIRECTOR TIDMARSH SAYS PRASAD ORCHESTRATED OUSTERTidmarsh lawsuit illuminates in-fighting under Makary, accuses Kevin Tang and Aurinia Pharmaceuticals of defamation
Industry
Drug Discovery and Development
Fresenius gets option rights on up to 37 first-to-market biosimilar candidates developed by WuXi Biologics, starting with copies of Roche's Polivy and Amgen's Tepezza. Fresenius picks the programs and keeps the economics; WuXi Biologics builds them for a per-program fee. The post…
Industry
Inside Precision Medicine
Cervical cancer rates and deaths are increasing around the world, with the highest rates in developing countries and regions like sub-Saharan Africa. The post Cervical Cancer Cases and Deaths Increasing, Particularly in Africa appeared first on Inside Precision Medicine.
Industry
Inside Precision Medicine
Researchers at Weill Cornell Medicine have discovered a genetic vulnerability in cancer cells that could make it possible to block WNT signaling without damaging healthy tissue. The findings point to a more selective treatment strategy for colorectal, breast and other cancers. Th…
Industry B BioPharm International
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
Industry
GEN
A study investigating the observed connection between pulmonary hypertension and cognitive decline symptoms has linked brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive disease in the lungs and heart. The post Inflammatory Process Identif…
Industry
Inside Precision Medicine
A new study suggests that gene expression patterns and tumor immune characteristics could help identify patients with small cell lung cancer who are more likely to experience favorable outcomes following immunotherapy. The post Molecular Profiling May Help Predict Immunotherapy O…
Industry P Pharmaceutical Commerce
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
Industry B BioPharm International
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
Industry
European Biotechnology
Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics approach the end of their patent protection and biosimilars could become an impo…
Industry
BioPharma Dive
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.
Industry
STAT Biotech
Five Bay Area labs teamed up to compare lasting effects of psilocybin on anxiety and depression-like behavior in mice, with limited results:
Industry
MedTech Dive
Abbott said it is facing pricing pressure and slower growth ahead of a planned coverage expansion for people with Type 2 diabetes. Competitor Dexcom, however, did not experience the same slowdown.
Industry
Pharmaceutical Technology
The deal covers assets that target more than €370bn in originator sales.
Industry
MedTech Dive
In a year where companies are grappling with cyberattacks, inflation and potential tariffs, Farrell, who is also CEO of Resmed, shared a bird’s eye view of the issues.
Industry P Pharmaceutical Executive
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
Industry
BioSpace
Bioscience employment rose in 41 states, though not in California, according to a new report from the Biotechnology Innovation Organization and the Council of State Bioscience Associations.
Industry
BioPharma Dive
A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
Industry P Pharmaceutical Commerce
Octapharma USA's Kerem Tokel, a LogiPharma USA 2026 freight security panelist, discusses theft hotspots, the export of stolen pharmaceutical loads and how to tighten chain of custody.
Industry
PharmaVoice
After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more targeted approach to new science.
Industry
MedCity News
[Sponsored] BTK inhibitor has become an important treatment option for certain B-cell malignancies. The post How Innovation in BTK Inhibitor Development Is Improving Treatment Outcomes appeared first on MedCity News.
Industry P pharmaphorum
On the benefits of earlier oncological intervention, with Johnson & Johnson Eloise.McLennan Mon, 02/11/2026 - 14:07
Industry P Practical Fragments
NMR was the first practical method used to identify fragments, described thirty years ago in this famous SAR by NMR paper. That headstart made NMR the go-to method for finding fragments, and as recently as ten years ago it was still in the lead, according to our poll in 2016…
Industry P PLOS Biology
by Abigail R. Marshall, Andrea Krstevski, Henry Crosswell, Rahul Shah, Eirini Maniou, Nicholas D. E. Greene, Andrew J. Copp, Gabriel L. Galea Epithelial fusion is critical for formation of many embryonic tissues. The developing mammalian spinal cord fuses by zippering, through ce…
Industry P PLOS Biology
by Rosanna C. T. Wright, Simon C. Lovell, Anna Richmond, Christian Harrison, Eleri Ashworth, Aras Kadioglu, Joanne L. Fothergill, Ville-Petri Friman, Edze R. Westra, Michael A. Brockhurst Only a fraction of bacterial genomes encode CRISPR-Cas systems, but the selective causes of…
Industry P PLOS Biology
by Siyu Deng, Chaogu Zheng In animal development, cells exit the cell cycle after a final round of cell division to differentiate into specialized cell types. However, the impact of failed cytokinesis on the fate specification of postmitotic cells, especially neurons, remains poo…
Industry P PLOS Biology
by Yumeng Ma, Philip A. Kragel Human emotional experiences vary widely in everyday life, yet they are systematically organized within a continuous affective space defined by valence and arousal. Although this circumplex organization has shaped decades of research, its neural impl…
Industry P PLOS Biology
by Liya Mathew, Sean L. Carlson, Michael Savage, Claire Pardieu, Megan B. O’Brien, Ellie Crawley, Paul Harrow, Ann-Kristin Kaune, Edward Devlin, Emily L. Priest, Marilena Crescente, Kimberly Martinod, James Boot, SoFong Cam Ngan, Marco Gasparetto, Klaartje Kok, James O. Lindsay,…
Industry
TechCrunch Biotech and Health
TechCrunch Founder Summit happens on November 4 in Boston for a founder-focused agenda and impactful connections. Save up to $100 or get discounts with group passes.